Analysis of PK data from Phase 1 Multi-Ascending Dose ("MAD") clinical trial completed
Data observed shows that fezagepras has nitrogen scavenging properties
Planned Phase 1a Single Ascending Dose ("SAD") trial, commencing in Q2 2022, to compare fezagepras with sodium phenylbutyrate as a nitrogen scavenger
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.